drugset / Trial / NCT05363501

Pharmacokinetic Evaluation of a New Naloxone Nasal Swab, Naloxone Nasal Spray, and Intramuscular Naloxone Injection in Healthy Volunteers

NCT05363501

Phase 1 Completed 76 enrolled Pocket Naloxone Corp
RandomizedCrossoverSingle-blindTreatment

Summary

The study consists of two Phases with the first phase (Pilot Phase) divided into two sub phases. In each study phase, subjects will be admitted to the clinical unit from 10 hours prior to the first drug administration on Day -1 until approximately 12 hours following the last study drug administration. Screening of alcohol and drugs of abuse will be performed before the first study drug administration. For female subjects, a pregnancy test will be performed before the first drug administration. Clinical nasal irritation rating and the Brief Smell Identification Test will be performed at screening.

Timeline

Start
2021-01-21
Primary completion
2022-04-03
Completion
2022-04-11

Drugs

EvaluationDrugModalityDoseRoute
Comparator Naloxone Small molecule 0.4 mg Intramuscular
Comparator Naloxone Small molecule 4 mg Intramuscular
Comparator Naloxone Small molecule 8 mg Intramuscular
Comparator Naloxone Small molecule 12 mg Intramuscular
Comparator Naloxone Small molecule 12.5 mg Intramuscular